Anti-retropulsion Devices

Anti-retropulsion Devices

The anti-retropulsion devices market is expected to register a CAGR of approx. 5.2% over the period of 2023-2030. The antiretropulsion device market refers to the segment of the medical device industry focused on devices designed to prevent stone migration during endoscopic procedures, particularly in the field of urology. These devices are utilized during procedures such as ureteroscopy to enhance the efficacy and safety of stone removal by minimizing the risk of stone migration back into the kidney or other parts of the urinary tract. The rising incidence and prevalence of urolithiasis (urinary tract stones) globally have heightened the demand for effective and minimally invasive treatment options, thereby driving the adoption of antiretropulsion devices in endourological procedures. For instance, according to the NCBI, In 2019, 11,55,52,140 incident cases of urolithiasis with 6,04,308.9 attributed DALYs and 13,278.9 deaths occurred globally. Furthermore, Continuous innovation and advancements in antiretropulsion device technology, including the development of devices with enhanced maneuverability, flexibility, and compatibility with endoscopic equipment, are driving market growth.

• Based on the end-user, the market has been categorized into hospitals, ambulatory surgical centers, others. Among them, the hospital category is to witness higher adoption of anti-retropulsion devices during the forecast period. The hospitals are witnessing a surge in admissions for urological disorders, including urinary tract stones, necessitating the utilization of antiretropulsion devices in endourological procedures to optimize patient outcomes. Moreover, hospitals are equipped with advanced infrastructure, state-of-the-art endoscopic equipment, and specialized facilities that facilitate the effective utilization of antiretropulsion devices in minimally invasive urological procedures. Furthermore, hospitals often have specialized urology departments and skilled healthcare professionals proficient in endourological interventions, thereby fostering the adoption and integration of antiretropulsion devices in urological care pathways.
• For a better understanding of the market adoption of the anti-retropulsion devices industry, the market is analyzed based on its worldwide presence in the countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. The North America Anti-retropulsion Devices market is expected to continue to grow in the coming years, driven by the increasing prevalence of urolithiasis and growing awareness of anti-retropulsion devices among healthcare professionals and the general population, development of training and education and the rise in healthcare expenditure. For instance, in 2020, according to census.gov, The older population increased by 50.9 million, from 4.9 million (or 4.7% of the total U.S. population) in 1920 to 55.8 million (16.8%) in 2020.
• Some of the major players operating in the market include Accordion Medical, AstraZeneca pharma, Boston cientific Corporation, Cook, Teleflex Incorporated, NIKSAN PHARMACEUTICAL, AdvaCare Pharma, Omicron Pharma, Cadila Pharmaceutical, ORFE MEDICAL.